Advertisement
Letters
JAMA. 1993;270(16):1934-1935. doi: 10.1001/jama.1993.03510160052025

Azithromycin in Chlamydial Urethritis

  1. Kimberly A. Workowski, MD
  1. Emory University Atlanta, Ga
  1. Raymond B. Johnson, MD
  1. Pfizer Central Research Groton, Conn
  1. Michael Verdon, PA;
  2. Walter E. Stamm, MD
  1. University of Washington Seattle

Since this article does not have an abstract, we have provided the first 150 words of the full text.

Excerpt

To the Editor. —A single 1-g dose of azithromycin has recently demonstrated effectiveness in treating uncomplicated genital chlamydial infection.1 As such, azithromycin represents a major advance in the treatment of chlamydial infection and may improve our efforts to limit the spread of this important pathogen. In view of the proven efficacy of the 1-g regimen, we examined whether a lower dose (500 mg) might be as effective in treating chlamydial infection. A lower dose would cost less and might be associated with fewer side effects. Since the mean tissue concentration after a 500-mg dose of azithromycin ranges between 1 and 9 mg/kg, with levels remaining above 1 mg/kg for 2 to 3 days,2 the expected tissue levels exceed the 90% minimum inhibitory concentration of Chlamydia trachomatis (0.25 mg/L) for at least several days.3

Eleven men with nongonococcal urethritis, characterized by urethral discharge, microscopic leukocytosis, and positive rapid

« Previous | Next Article »Table of Contents

More in JAMA & Archives Journals